

Apoptosis (Programmed Cell Death) and the Resolution of Acute Inflammation

A.H. ROUZATI, R. TANEJA, J.C. MARSHALL

Biology, for the clinician, has classically encompassed the study of the life and growth of cells and organisms; death has been perceived as a pathologic process to be prevented. But over the past few years, our perception of cell death has undergone a major transformation [1]. It is now recognized that cells do not have an absolute and unchangeable lifespan, but rather that cell survival can change in response to environmental stimuli. Moreover, a moment's reflection will confirm that for a host of normal biologic processes, controlled cellular death is not only inevitable, but critical to normal development. During embryogenesis, the formation of mature organs is dependent on the controlled remodeling of tissues resulting, for example, in the formation of interdigital web spaces or the canalization of the gastrointestinal tract. Deletion of autoreactive T cells during immune maturation is essential to prevent autoimmune disease; other tissues such as blood cells, and epithelial cells of the skin, or gastrointestinal tract are constantly formed and shed during life. The programmed death of cells is called *apoptosis*.

Apoptosis and necrosis

Cells can die a pathological or physiological death [2]. *Necrosis* is the pathological form of cell death, and not the mechanism by which cells usually die. Necrosis typically occurs when the environment of the cell is unable to support cellular metabolic needs, either because of an acute deficiency of a vital substrate such as oxygen or nutrients, or because of exposure to substances that are toxic to the vital processes of the cell. Necrosis is characterized by uncontrolled changes in cellular architecture and function, leading to the release of intracellular contents into the cellular microenvironment. The necrotic cell swells, and the membrane ruptures; intracellular contents evoke an inflammatory response, leading to the phagocytosis of cellular debris.

Apoptosis, on the other hand, is a tightly controlled process, initiated through the expression of an endogenous cell death program, and brought about through the sequential and co-ordinated action of intracellular enzymes. In contrast to the necrotic cell, the apoptotic cell shrinks, its chromatin condenses, and the in-

tracellular contents become organized into membrane-bound organelles known as apoptotic bodies. These apoptotic bodies are rapidly and efficiently removed by cells of the reticuloendothelial system, without evoking an inflammatory response. The process of apoptosis proceeds rapidly *in vivo*, and may be missed in tissue sections, although apoptotic cells are recognized occasionally as pyknotic cells.

Mechanisms of apoptosis

Apoptosis is a highly conserved process in evolution. In fact, contemporary understanding of the cellular mechanisms of apoptosis is grounded in studies of the mechanisms of embryologic cell death in the nematode, *Caenorhabditis elegans*. During its maturation to an adult worm, *C. elegans* loses exactly 131 cells through apoptosis, leaving 959 cells [3] 2 genes, *ced-3* and *ced-4*, which stimulated apoptosis [4] and one gene, *ced-9*, which inhibited it [5]. A human homolog of *ced-9* was identified in a B-cell lymphoma and thus called *bcl-2* [6]. *Bcl-2* proved to be a mitochondrial protein involved in cytochrome c and calcium transport that served as an inhibitor of apoptosis in human cells [7]. It is now recognized as one of a larger family of proteins which includes proteins that both stimulate (*bax*) and inhibit (*bcl-2*, *bad*) apoptosis.

The search for a human *ced-3* homolog identified the interleukin-1 β converting enzyme (ICE) as the first member of a family of intracellular proteins that are capable of inducing apoptosis [8]. To date, at least 11 members of this family have been identified [9]. All are cysteine proteases that share the common feature of cleaving their substrates at sites adjacent to aspartic acid residues. Proteins of this family have been termed *caspases* (cysteine proteases with aspartic acid targets) [10]; ICE is now more commonly referred to as caspase-1. Caspase targets within the cell include proteins ranging from DNA repair enzymes such as poly-ADP ribose polymerase to cytoskeletal proteins including actin; they also cleave pro-forms of each other, yielding active caspase enzymes.

Apoptosis proceeds spontaneously in a variety of cell types; the apoptotic program can also be induced through signals from the environment. For instance, the engagement of a cell surface receptor called Fas by its ligand, Fas ligand, leads to caspase activation and apoptosis [11]. Interactions between Fas and Fas ligand are responsible for the maintenance of immune privilege in anatomic environments such as the anterior chamber of the eye [12]. Conversely, deficiency of Fas or Fas ligand in animals [13] or humans [14] results in the development of autoimmunity. Another well known member of this family of cell surface death receptors is the receptor for the cytokine, tumour necrosis factor (TNF), whose engagement can also induce apoptosis [15, 16]. Indeed induction of apoptosis by TNF represents the mechanism of its anti-tumour activity [17].

The final consequence of initiation of the apoptotic program is nuclear fragmentation and plasma membrane changes leading to the formation of apoptotic bodies. The nuclear changes of apoptosis can be recognized through the formation of a characteristic ladder pattern on DNA gel electrophoresis, or by flow cytometry as reduced uptake of the nuclear dye, propidium iodide. Membrane changes of apoptosis include exteriorization of phosphatidyl serine, normally located on the inner aspect of the plasma membrane, detectable as binding of annexin V by flow cytometry [18].

Apoptosis in the pathogenesis of critical illness

Alterations in the expression of apoptosis – both acceleration and inhibition of the apoptotic program – appear to play a role in the pathogenesis of critical illness.

In 1995, Teodorczyk-Injeyan et al. showed that lymphocyte apoptosis is accelerated following burn injury, and is responsible for burn-associated lymphopenia [19]. Similar conclusions have been drawn in a rat model of burn injury in which enhanced thymocyte apoptosis is associated with immune dysfunction [20]. Fas-mediated apoptosis of circulating lymphocytes is also increased following major surgery [21].

Hepatocytes express the Fas receptor and are very sensitive to its stimulation [22]. As a result, various forms of liver injury have been associated with abnormalities in apoptosis. Apoptosis is thought to play an important role in such pathological conditions as toxic and metabolic liver injury (for example, alcoholic cirrhosis), immune-mediated injury (for example, host-versus-allograft reaction in allograft rejection) and various viral liver diseases [23]. Liver failure in patients suffering from viral fulminant hepatitis has been shown to be a result of the apoptotic death of Fas expressing hepatocytes [24]. Similarly, interactions between Fas and its physiologic ligand have been implicated in the pathogenesis of acute Wilson's disease, with activation of Fas as consequence of the interaction of the hepatocyte with copper [25]. Injection of mice with anti-Fas antibody results in fulminant liver failure as a consequence of increased hepatocyte apoptosis [26]. Furthermore, accelerated apoptosis has been implicated as the mechanism of tissue injury in the liver and spleen in experimental endotoxin shock [27].

Under normal physiologic conditions, the expression of apoptosis in the adult kidney is uncommon. However, apoptosis appears to play a role in a number of pathologic states. Experimental models of partial ureteric obstruction and renal artery stenosis reveal an important relationship between restricted renal blood supply and loss of renal mass due to apoptotic cell death [28]. Diabetes and hypertension associated renal damage have also been shown to involve apoptosis, as has immune mediated glomerulonephritis [29].

The exotoxin of *Clostridium difficile*, the causative agent of pseudomembranous colitis, has been demonstrated to induce the apoptosis of intestinal epithelial cells [30]. Inhibition of apoptosis by viral proteins is a common mechanism in acute viral infections [31, 32]. In contrast, HIV infection induces lymphopenia, in part, through the effects of the virus in upregulating expression of Fas ligand on host macrophages [33].

Delayed neutrophil apoptosis in systemic inflammation

Impaired expression of apoptosis may also contribute to the pathogenesis of critical illness. The development of a syndrome of sustained and exaggerated inflammation, popularly known as the Systemic Inflammatory Response Syndrome (SIRS) [34], is the predominant risk factor for the development of the multiple organ dysfunction syndrome (MODS), the leading cause of death in critical illness [35]. While infection is an important cause of SIRS, the syndrome can also develop following multiple trauma, burns, acute pancreatitis, major surgery, and other acute insults associated with the activation of an endogenous inflammatory response.

Through the release of proteases and toxic oxygen metabolites, neutrophils play an important role in the pathophysiology of SIRS as mediators of tissue injury and organ dysfunction [36, 37]. The lifespan of the neutrophil in vivo is short, probably not longer than 5 or 6 hours, and is terminated through the activation of a constitutively expressed cell death program that induces neutrophil apoptosis, and their removal by cells of the reticuloendothelial system [18]. Thus neutrophil-mediated inflammation is terminated through the programmed cell death of the neutrophil. Expression of apoptosis can be inhibited by a large number of inflammatory mediators of both microbial and host origin [38, 39]. The stimuli that inhibit the constitutive expression of neutrophil apoptosis are many, and include microbial products such as endotoxin and fMLP, cytokines such as IL-1 β , IL-8, and GM-CSF, and the process of transmigration into an inflammatory focus, or the cross-linking of cell surface β 2 integrins [40].

Neutrophil apoptosis and the pathogenesis of ARDS

Although the acute respiratory distress syndrome has been described in neutropenic patients [41], a large body of clinical and experimental data supports the concept that neutrophils contribute to the evolution of acute lung injury [42]. Autopsy studies typically show massive accumulation of neutrophils in the lungs of patients with ARDS, and, at least in ARDS associated with sepsis, non-survivors show persistently higher numbers of neutrophils on bronchoalveolar lavage [43]. Concentrations of the PMN chemoattractant, IL-8, are increased in BAL fluid, and correlate with both neutrophil counts and increased risk of mor-

tality [44]. Neutrophils recovered from the lung of the patient with ARDS are activated, as manifested by increased expression of $\beta 2$ integrins and shedding of L-selectin [45]. Moreover patients with ARDS have elevated levels of hydrogen peroxide in the exhaled gas [46]. Finally, there are at least two case reports documenting deterioration of ARDS in critically ill patients given G-CSF [47] or GM-CSF [48], cytokines that increase circulating neutrophil numbers by augmenting their release from the bone marrow, and by inhibiting apoptosis.

There is no evidence that neutrophils that have migrated into the injured lung are able to return to the blood stream, nor that lymphatic drainage provides an important disposal route [49]. Thus the removal of neutrophils from the lung in ARDS appears to require the apoptotic death of the cell [50]. Lung neutrophil apoptosis is delayed during experimental acute lung injury [51], as well as in patients with ARDS [52]. BAL fluid from patients with ARDS inhibits the apoptosis of control neutrophils, an effect that can be reversed with antibodies to G-CSF or GM-CSF [52]. Serial studies in ARDS have suggested that patients who survive ARDS following sepsis have an increase in alveolar macrophage neutrophil ratio over time [53], consistent with the removal of neutrophils by macrophages. The cytokine, IL-10, has also been shown to hasten the resolution of pulmonary inflammation by promoting the restoration of normal neutrophil apoptosis [54].

Neutrophil apoptosis in SIRS

Neutrophils collected from patients following burn injury showed delayed apoptosis; the apoptotic delay can be reversed with a neutralizing antibody to GM-CSF [55]. Similar observations have been made in victims of multiple trauma: delayed neutrophil apoptosis is partially reversed by neutralization of G-CSF, but not of GM-CSF [56]. Our group has shown that patients with SIRS, and patients who have undergone major elective surgery (elective repair of an abdominal aortic aneurysm), show delayed neutrophil apoptosis (Fig. 1), in association with evidence of neutrophil activation, reflected in augmented respiratory burst activity [57] (Fig. 2). This delay is at least partially mediated by antiapoptotic factors in the plasma, as plasma from patients with SIRS is able to delay the apoptosis of normal control neutrophils.

Conclusions

A better understanding of the mechanisms of apoptosis should lead to new approaches to treat a broad spectrum of diseases. New therapeutic strategies will emerge as the molecular mechanisms involved in the cell's program of apoptosis are defined. For example, caspase inhibitors have been shown to have a protective effect in animal models of apoptosis induced liver disease caused by en-




Fig. 1.

Expression of apoptosis is inhibited in patients with SIRS, or those who have undergone an elective repair of an abdominal aortic aneurysm. Rates of apoptosis were determined as the uptake of propidium iodide by flow cytometry. Modified from [57]




Fig. 2.

Concomitant with delayed apoptosis, neutrophils from patients with SIRS, or patients having undergone elective aneurysmectomy, show enhanced respiratory burst activity; data reflect log mean channel fluorescence of dihydrorhodamine 123. Modified from [57]

gement of the Fas or TNF [58]. Other agents capable of modulating the expression of apoptosis may find a role in the treatment of SIRS in the ICU setting. For example, the normal expression of apoptosis in inflammatory neutrophils can be restored by inhibition of ICE [59], by IL-10 [54], or by inhibition of calpain [60]. Ironically, an improved understanding of the mechanisms of cell death may provide new insights into preventing mortality in the ICU.

References

1. Hets SE (1998) To die or not to die: an overview of apoptosis and its role in disease. *JAMA* 279:300-307
2. Majno G, Joris I (1995) Apoptosis, oncosis, and necrosis. An overview of cell death. *Am J Pathol* 146:3-15
3. Ellis RE, Yuan J, Horvitz HR (1991) Mechanisms and function of cell death. *Ann Rev Cell Dev Biol* 7:663-698
4. Yuan J, Horvitz HR (1990) The *Caenorhabditis elegans* genes *ced-3* and *ced-4* act cell autonomously to cause programmed cell death. *Dev Biol* 138:33-41
5. Hengartner MO, Ellis RE, Horvitz HR (1992) *Caenorhabditis elegans* gene *ced-9* protects cells from programmed cell death. *Nature* 356:494-499
6. Yang E, Korsmeyer SJ (1996) Molecular thanatopsis: A discourse on the Bcl-2 family and cell death. *Blood* 88:386-401
7. Yang J, Liu XS, Bhalla K et al (1997) Prevention of apoptosis by Bcl-2: Release of cytochrome c from mitochondria blocked. *Science* 275:1129-1132
8. Yuan J, Shaham S, Ledoux S et al (1993) The *C. elegans* cell death gene *ced-3* encodes a protein similar to mammalian interleukin 1 β converting enzyme. *Cell* 75:641-652
9. Alnemri ES (1997) Mammalian cell death proteases: a family of highly conserved aspartate specific cysteine proteases. *J Cell Biochem* 64:33-42
10. Alnemri ES, Livingston DJ, Nicholson DW et al (1996) Human ICE/CED-3 protease nomenclature. *Cell* 87:171
11. Nagata S, Golstein P (1995) The Fas death factor. *Science* 267:1449-1456
12. Griffith TS, Brunner T, Fletcher SM et al (1995) Fas ligand-induced apoptosis as a mechanism of immune privilege. *Science* 270:1189-1192
13. Takahashi T, Tanaka M, Brannan CI et al (1994) Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. *Cell* 76:969-976
14. Rieux-Laucat F, Le Deist F, Hivroz C et al (1995) Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. *Science* 268:1347-1349
15. Boldin MP, Goncharov TM, Goltsev YV et al (1996) Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1- and TNF receptor-induced cell death. *Cell* 85:803-815
16. Wallach D, Boldin M, Varfolomeev E et al (1997) Cell death induction by receptors of the TNF family: towards a molecular understanding. *FEBS Lett* 410:96-106
17. Woods KM, Chapes SK (1993) Three distinct cell phenotypes of induced-TNF cytotoxicity and their relationship to apoptosis. *J Leuk Biol* 53:37-44
18. Savill JS, Wyllie AH, Henson JE et al (1989) Macrophage phagocytosis of aging neutrophils in inflammation. *J Clin Invest* 83:865-875
19. Teodorczyk-Injeyan JA, Cembrznska-Nowak M, Lalani S et al (1995). Immune deficiency following thermal trauma is associated with apoptotic cell death. *J Clin Immunol* 15:318-328
20. Nakanishi T, Nishi Y, Sato EF et al (1998) Thermal injury induces thymocyte apoptosis in rats. *J Trauma* 44:143-148

21. Oka M, Hirazawa K, Yamamoto K et al (1996) Induction of Fas-mediated apoptosis on circulating lymphocytes by surgical stress. *Ann Surg* 223:434-440
22. Feldman G (1997) Liver apoptosis. *J Hepatol* 26:1-11
23. Galle PR (1997) Apoptosis in liver disease. *J Hepatol* 27:405-412
24. Galle PR, Hofmann WJ, Walczak H et al (1995) Involvement of the CD95(APO-1/Fas) receptor and ligand in liver damage. *J Exp Med* 182:1223-1230
25. Strand S, Hofmann WJ, Grambihler A et al (1998) Hepatic failure and liver cell damage in acute Wilson's disease involve CD95 (APO-1/Fas) mediated apoptosis. *Nature Med* 4:588-593
26. Lacroix V, Mignon A, Fabre M et al (1996) Bcl-2 protects against lethal hepatic apoptosis induced by an anti-Fas antibody in mice. *Nature Med* 2:80-86
27. Haendeler J, Messmer UK, Brune B et al (1996) Endotoxin shock leads to apoptosis in vivo and reduces bcl-2. *Shock* 6:405-409
28. Gobe GC, Axelsen RA, Searle JW (1990) Cellular events in experimental unilateral ischemic renal atrophy and in regeneration after contralateral nephrectomy. *Lab Invest* 56:770-779
29. Buttyan R, Gobe G (1997) Apoptosis in the mammalian kidney: incidence, effectors, and molecular control in normal developmental and disease states. *Adv Pharmacol* 41:369-381
30. Mahida YR, Makh S, Hyde S et al (1996) Effect of *Clostridium difficile* toxin A on human intestinal epithelial cells: induction of interleukin 8 production and apoptosis after cell detachment. *Gut* 38:337-347
31. Ray CA, Black RA, Kronheim SR et al (1992) Viral inhibition of inflammation: Cowpox virus encodes an inhibitor of the interleukin-1 beta converting enzyme. *Cell* 69:597-604
32. Leopardi R, Roizman B (1996) The herpes simplex virus major regulatory protein ICP4 blocks apoptosis induced by the virus or by hyperthermia. *Cell Biol* 93:9583-9587
33. Badley AD, McElhinny JA, Leibson PJ et al (1996) Upregulation of Fas ligand expression by human immunodeficiency virus in human macrophages mediates apoptosis of uninfected T lymphocytes. *J Virol* 70:199-206
34. Bone RC, Balk RA, Cerra FB et al (1992) Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. *Chest* 101:1644-1655
35. Beal AL, Cerra FB (1994) Multiple organ failure syndrome in the 1990's. Systemic inflammatory response and organ dysfunction. *JAMA* 271:226-233
36. Weiss SJ (1989) Tissue destruction by neutrophils. *N Engl J Med* 320:365-376
37. Fujishima S, Aikawa N (1995) Neutrophil-mediated tissue injury and its modulation. *Intensive Care Med* 21:277-285
38. Lee A, Whyte MKB, Haslett C et al (1993) Inhibition of apoptosis and prolongation of neutrophil functional longevity by inflammatory mediators. *J Leuk Biol* 54:283-288
39. Marshall JC, Watson RWG (1997) Programmed cell death (apoptosis) and the resolution of systemic inflammation. *Can J Surg* 40:169-174
40. Watson RWG, Rotstein OD, Nathens AB et al (1997) Neutrophil apoptosis is modulated by endothelial transmigration and adhesion molecule engagement. *J Immunol* 158:945-953
41. Ognibene FP, Martin SE, Parker MM (1986) Adult respiratory distress syndrome in patients with severe neutropenia. *N Engl J Med* 315:547-551
42. Windsor ACJ, Mullen PG, Fowler AA et al (1993) Role of the neutrophil in adult respiratory distress syndrome. *Br J Surg* 80:10-17
43. Steinberg KP, Milberg JA, Martin TR et al (1994) Evolution of bronchoalveolar cell populations in the adult respiratory distress syndrome. *Am J Respir Crit Care Med* 150:113-122
44. Miller EJ, Cohen AB, Nagao S et al (1992) Elevated levels of NAP-1/interleukin-8 are present in the airspaces of patients with the adult respiratory distress syndrome and are associated with increased mortality. *Am Rev Respir Dis* 146:427-432
45. Cholle-Martin S, Jourdain B, Gibert C et al (1996) Interactions between neutrophils and cytokines in blood and alveolar spaces during ARDS. *Am J Respir Crit Care Med* 154:594-601
46. Baldwin SR, Grum CM, Boxer LA et al (1986) Oxidant activity in expired breath of patients with adult respiratory distress syndrome. *Lancet* 1:11-14

47. Schilero GJ, Oropello J, Benjamin E (1995) Impairment in gas exchange after granulocyte colony stimulating factor (G-CSF) in a patient with the adult respiratory distress syndrome. *Chest* 107:276-278
48. Verhoef G, Boogaerts M (1991) Treatment with granulocyte-macrophage colony-stimulating factor and the adult respiratory distress syndrome. *Am J Hematol* 36:285-287
49. Weiland JE (1986) Lung neutrophils in adult respiratory distress syndrome. Clinical and pathologic significance. *Am Rev Respir Dis* 133:218-225
50. Cox GJ, Crossley J, Xing Z et al (1995) Macrophage engulfment of apoptotic neutrophils contributes to the resolution of acute pulmonary inflammation in vivo. *Am J Respir Cell Mol Biol* 12:232-237
51. Watson RWG, Rotstein OD, Parodo J et al (1997) Impaired apoptotic death signaling in inflammatory lung neutrophils is associated with decreased expression of interleukin 1b converting enzyme family proteases (caspases). *Surgery* 122:163-172
52. Matute-Bello G, Liles WC (1997) Neutrophil apoptosis in acute respiratory distress syndrome. *Am J Respir Crit Care Med* 156:1969-1977
53. Steinberg KP, Milberg JA, Martin TR et al (1994) Evolution of bronchoalveolar cell populations in the adult respiratory distress syndrome. *Am J Respir Crit Care Med* 150:113-122
54. Cox G (1996) IL-10 enhances resolution of pulmonary inflammation in vivo by promoting apoptosis of neutrophils. *Am J Physiol* 271: L566-L571
55. Chitnis D, Dickerson C, Munster AM et al (1996) Inhibition of apoptosis in polymorphonuclear neutrophils from burn patients. *J Leuk Biol* 59:835-839
56. Ertel W, Keel M, Infanger M et al (1998) Circulating mediators in serum of injured patients with septic complications inhibit neutrophil apoptosis through up-regulation of protein tyrosine phosphorylation. *J Trauma* 44:767-776
57. Jimenez MF, Watson RWG, Parodo J et al (1997) Dysregulated expression of neutrophil apoptosis in the systemic inflammatory response syndrome (SIRS). *Arch Surg* 132:1263-1270
58. Rouquet N, Pages JC, Molina T et al (1996) ICE inhibitor YVAD-cmk is a potent therapeutic agent against in vivo liver apoptosis. *Curr Biol* 6:1192-1195
59. Watson RWG, Rotstein OD, Parodo J et al (1998) The interleukin-1 beta converting enzyme (caspase-1) inhibits neutrophil apoptosis through processing of interleukin-1. *J Immunol*
60. Lu Q, Mellgren RL (1996) Calpain inhibitors and serine protease inhibitors can produce apoptosis in HL-60 cells. *Arch Biochem Biophys* 334:175-181